Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.

Kolltan Pharmaceuticals (New Haven, CT) a development-stage biopharmaceutical company focused on monoclonal antibody oncology therapeutics, closed a $8.5M Series B financing. Participants include Celtic Therapeutics Holdings and Tichenor Ventures.

arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]

Morvus Technology (United Kingdom) a preclinical-stage pharmaceutical company focused on prodrug and anti-angiogenic oncology approaches, closed a $3.3M Series A financing. Participants were not identified.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Zyngenia (Rockville, MD) a pre-clinical stage biotherapeutics company focused on multi-specific antibodies for oncology and autoimmune disorders, closed a $10M Series A financing. Particpants include New Enterprise Associates.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

BioVex (Woburn, MA) a clinical-stage biologics company focused on metastatic melanoma, head and neck, pancreatic and colo-rectal cancer, closed a $30M Series F bringing the entire round to $70M. Participants have included Morningside Venture, Ventech, MVM Life Science Partners, Sectoral Asset Management, Ysios Capital Partners, Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris [...]

Elara Pharmaceuticals (Germany) a preclinical-stag biopharma focused on Hypoxia Inducible Factor antagonizing drugs for the treatment of different cancers, closed a $3.6M Series A financing. Participants include EMBL Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Bellicum Pharmaceuticals (Houston, TX) a clinical-stage biopharmaceutical company focused on immune-modulating therapeutic vaccines for prostate cancer, closed a $4.5M Series A financing. Particiapnts include the Texas Emerging Technology Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.